GR159897 is a nonpeptide antagonist of the neurokinin-2 (NK) receptor. It binds to NK receptors (K = 0.32 nM) and is selective for NK over NK and NK receptors in radioligand binding assays (Ks = 5,010 and >1,000 nM, respectively). GR159897 inhibits contractions induced by the NK receptor agonist GR64349 in isolated guinea pig trachea (pA = 8.7). In vivo GR159897 (0.12 mg/kg) inhibits GR64349-induced bronchoconstriction in anesthetized guinea pigs. GR159897 (0.2-50 µg/kg) increases the amount of time spent in the front of the cage during confrontation with a human observer, a marker of anxiolytic-like activity, in marmosets.
GR 159897 is a highly potent, selective, competitive, brain-penetrated non-peptide neurokinin 2 (NK2) receptor antagonist. GR 159897 has little or no affinity for NK1 and NK3 receptors. GR 159897 inhibits binding of [3H]GR100679 to human NK2 (hNK2)-CHO cells and rat colon membranes with pKis of 9.51 and 10, respectively. Antagonizes bronchoconstriction. Anxiolytic-like and anti-tumor effects.
体外研究
GR 159897 (10-30 μM; 72 hours; 4T1, 4THM, 4TLM and 67NR cells) treatment inhibits proliferation of cells in all cell lines dose- dependently, a response more pronounced in 4T1, 4THM and 4TLM cells compared to 67NR cells.
GR 159897 (10-30 μM; 72 hours; 4TBM, 4TLM, 4THM and 4T1 cells) treatment increases phosphorylation of P38, while inhibiting AKT activation in all metastatic cell lines whereas phosphorylation of ERK decreased in 4TBM, 4TLM and 4THM but not in 4T1 cells.
Cell Proliferation Assay
Cell Line:
4T1, 4THM, 4TLM and 67NR cells
Concentration:
10 μM, 30 μM
Incubation Time:
72 hours
Result:
Inhibited proliferation of cells in all cell lines dose- dependently, a response more pronounced in 4T1, 4THM and 4TLM cells compared to 67NR cells.
Western Blot Analysis
Cell Line:
4TBM, 4TLM, 4THM and 4T1 cells
Concentration:
10 μM, 30 μM
Incubation Time:
40 hours
Result:
Increased phosphorylation of P38.
体内研究
GR 159897 (0.12 mg/kg; intravenous injection; guinea-pigs) treatment potently antagonizes bronchoconstriction induced by GR64349, with a long duration of action (3 h).
Animal Model:
Guinea-pigs
Dosage:
0.12 mg/kg
Administration:
Intravenous injection
Result:
Potently antagonised bronchoconstriction induced by GR64349, with a long duration of action (3 h).